SOCIAL MEDIA

ProfilePicture.png

Twitter

Targeted Oncology LCSM: 16/05/2021 10:00:38


More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study. #LCSM


Read more

ProfilePicture.png

Twitter

OncLive.com lcsm: 16/05/2021 11:00:12


The immunotherapy regimen also continued to significantly improve progression-free survival in this patient population over chemotherapy alone. #lcsm


Read more

ProfilePicture.png

Twitter

A/Prof Tim Clay lcsm: 16/05/2021 12:49:22


Catching up on my journal articles Excellent review from @MNagasaka and colleagues in @JTOonline on history/future of third generation EGFR inhibitors in NSCLC #lcsm @EGFRResisters


Read more